Abstract
Understanding the temporal relationship between key events in an individual’s infection history is crucial for disease control. Delay data between events, such as infection and symptom onset times, is doubly censored because the exact time at which these key events occur is generally unknown. Current mathematical models for delay distributions rely solely on heuristic justifications for their applicability. Here, we derive a new model for delay distributions, specifically for incubation periods, motivated by bacterial-growth dynamics that lead to the Burr family of distributions being a valid modelling choice. We also incorporate methods within these models to account for the doubly censored data. Our approach provides biological justification in the derivation of our delay distribution model, the results of fitting to data highlighting the superiority of the Burr model compared to currently used models in the literature. Our results indicate that the derived Burr distribution is 13 times more likely to be a better-performing model to incubation-period data than currently used methods. Further, we show that incorporating methods for handling the censoring issue results in the mean of the underlying continuous incubation-period model being reduced by a whole day, compared to the mean obtained under alternative modelling techniques in the literature.
Author summary In public health, it is important to know key temporal properties of diseases (such as how long someone is ill for or infectious for). Mathematical characterisation of properties requires information about patients’ infection histories, such as the number of days between infection and symptom onset, for example. These methods provide useful insights, such as how their infectiousness varies over time since they were infected. However, two key issues arise with these approaches. First, these methods do not have strong arguments for the validity of their usage. Second, the data typically used is provided as a rounded number of days between key events, as opposed to the exact period of time. We address both these issues by developing a new mathematical model to describe the important properties of the infection process of various diseases based on strong biological justification, and further incorporating methods within the mathematical model which consider infection and symptom onset to occur at any point within an interval, as opposed to an exact time. Our approach provides more preferable results, based on AIC, than existing approaches, enhancing the understanding of properties of diseases such as Legionnaires’ disease.
Competing Interest Statement
The authors have declared no competing interest.
Funding Statement
This study did not receive any funding. NJ acknowledges support from the Engineering and Physical Sciences Research Council (EPSRC) and Mathematics and Data in Scientific and Industrial Modelling (MADSIM) at the University of Manchester for funding of their studentship. IH was supported by the JUNIPER modelling consortium (grant MR/V038613/1) the National Core Study on Transmission (PROTECT) and by the UKRI Impact 553 Acceleration Account (IAA 386). NJ and IH also acknowledge the UK Health Security Agency (UKHSA) for honorary contracts and funding (for IH). The views expressed are those of the author(s) and not necessarily those of the Department of Health or UKHSA.
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
This study used ONLY openly available human data that were originally located at: https://pubmed.ncbi.nlm.nih.gov/21242803/ https://pubmed.ncbi.nlm.nih.gov/7973702/ https://bmcinfectdis.biomedcentral.com/articles/10.1186/s12879-018-3391-3 https://pubmed.ncbi.nlm.nih.gov/28669361/
I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.
Yes
Data Availability
All data produced in the present work are contained in the manuscript and referenced papers.
https://pubmed.ncbi.nlm.nih.gov/28669361/
https://bmcinfectdis.biomedcentral.com/articles/10.1186/s12879-018-3391-3